Status:
RECRUITING
Immunologic Response to Pneumococcal Polysaccharide Vaccine in Splenic Injury Patients
Lead Sponsor:
University of California, Davis
Conditions:
Asplenia
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
Persons without a spleen are susceptible to potentially lethal infections from certain bacteria, with pneumococcus being the most prevalent. Vaccines are provided to help protect against these infecti...
Detailed Description
The study is a multi-institutional, prospective trial, conducted primarily at the University of California, Davis Medical Center (UCDMC) by the Department of Surgery, Division of Trauma and Acute Care...
Eligibility Criteria
Inclusion
- Adult trauma patients (aged 18 to 65 years old) sustaining a splenic injury.
Exclusion
- Ages less than 18 and greater than 65
- Initial planned nonoperative management patient who subsequently undergoes embolization or splenectomy will be withdrawn from the study.
Key Trial Info
Start Date :
December 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2026
Estimated Enrollment :
75 Patients enrolled
Trial Details
Trial ID
NCT02232191
Start Date
December 1 2014
End Date
July 1 2026
Last Update
December 5 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of California, Davis Medical Center
Sacramento, California, United States, 95817